6533b86efe1ef96bd12cb581

RESEARCH PRODUCT

No Evidence for Classic Thrombotic Microangiopathy in COVID-19

Tanja FalterSven DanckwardtHeidi RossmannSteffen GroenwoldtPeter R. GalleJan GoetjeVisvakanth SivanathanArndt WeinmannInge ScharrerBernhard LämmleBernhard LämmleBernhard LämmlePhilipp MengeKarl J. LacknerNiels A. W. LemmermannAndreas SchulzMartin F. Sprinzl

subject

medicine.medical_specialtyThrombotic microangiopathymicroangiopathylcsh:Medicine030204 cardiovascular system & hematologyFibrinogenGastroenterologyArticleProcalcitonin03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal medicineMedicinePlateletdisseminated intravascular coagulationDisseminated intravascular coagulationbusiness.industrylcsh:RMicroangiopathyCOVID-19General Medicinemedicine.diseaseADAMTS13ADAMTS13Blood pressurecoronavirus disease030220 oncology & carcinogenesisbusinessmedicine.drug

description

Background: Coronavirus disease-2019 (COVID-19) triggers systemic infection with involvement of the respiratory tract. There are some patients developing haemostatic abnormalities during their infection with a considerably increased risk of death. Materials and Methods: Patients (n = 85) with SARS-CoV-2 infection attending the University Medical Center, Mainz, from 3 March to 15 May 2020 were retrospectively included in this study. Data regarding demography, clinical features, treatment and laboratory parameters were analyzed. Twenty patients were excluded for assessment of disseminated intravascular coagulation (DIC) and thrombotic microangiopathy (TMA) due to lack of laboratory data. Results: COVID-19 patients (n = 65) were investigated, 19 with uncomplicated, 29 with complicated, and 17 with critical course

yearjournalcountryeditionlanguage
2021-02-01Journal of Clinical Medicine
https://doi.org/10.3390/jcm10040671